Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Samuraciclib · CT-7001, ICEC-0942

Small molecule · Inhibitor of CDK7 · developed by Carrick Therapeutics

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Samuraciclib?

Samuraciclib is an orally available, selective CDK7 inhibitor that competitively binds the CDK7 ATP binding site to inhibit CDK7-mediated signaling. By blocking CDK7, which regulates cell cycle progression and transcriptional regulation through RNA polymerase II phosphorylation, the drug may inhibit tumor cell proliferation in CDK7-dependent cancers. It is being studied in breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CT-7001, ICEC-0942
Drug type
Small molecule
Targets
CDK7
Mechanism
Inhibitor of CDK7
Pathways
cell cycle progression, transcriptional regulation, RNA polymerase II phosphorylation
Therapy area
Oncology
Developer
Carrick Therapeutics Limited
In trials of
ARVN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
46D4HS9ODA

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06125522 Phase 1/2 Breast Cancer Completed ARVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.